Literature DB >> 19636529

Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications.

A Bierhaus1, P P Nawroth.   

Abstract

The pattern recognition receptor or receptor for AGE (RAGE) is constitutionally expressed in a few cell types only. However in almost all cells studied so far it is induced by reactions known to initiate inflammation. Its biological activity seems to be mainly dependent on the presence of its various ligands, including AGE, S100-calcium binding protein/calgranulins, high-mobility group protein 1, amyloid-beta-peptides and the family of beta-sheet fibrils, all known to be elevated in chronic metabolic, malignant and inflammatory diseases. The RAGE pathway interacts with cytokine-, lipopolysaccharide-, oxidised LDL- and glucose-triggered cellular reactions by turning a short-lasting inflammatory response into a sustained change of cellular function driven by perpetuated activation of the proinflammatory transcription factor, nuclear factor kappa-B. RAGE-mediated persistent cell activation is of pivotal importance in various experimental and clinical settings, including diabetes and its complications, neurodegeneration, ageing, tumour growth, and autoimmune and infectious inflammatory disease. Due to RAGE's central role in maintaining perpetuated cell activation, various therapeutic attempts to block RAGE or its ligands are currently under investigation. Despite broad experimental evidence for the role of RAGE in chronic disease, knowledge of its physiological function is still missing, limiting predictions about safety of long-term inhibition of RAGE x ligand interaction in chronic diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19636529     DOI: 10.1007/s00125-009-1458-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  107 in total

1.  N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response.

Authors:  Timo M Buetler; Estelle Leclerc; Alexandra Baumeyer; Helia Latado; John Newell; Oskar Adolfsson; Véronique Parisod; Janique Richoz; Sarah Maurer; Francis Foata; Dominique Piguet; Sylviane Junod; Claus W Heizmann; Thierry Delatour
Journal:  Mol Nutr Food Res       Date:  2008-03       Impact factor: 5.914

2.  Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5' regulatory region on chromosome 3: implications for polymorphic studies in diabetes.

Authors:  B I Hudson; M H Stickland; P J Grant; T S Futers
Journal:  Diabetes       Date:  2001-12       Impact factor: 9.461

3.  A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin.

Authors:  Valeria V Orlova; Eun Young Choi; Changping Xie; Emmanouil Chavakis; Angelika Bierhaus; Eveliina Ihanus; Christie M Ballantyne; Carl G Gahmberg; Marco E Bianchi; Peter P Nawroth; Triantafyllos Chavakis
Journal:  EMBO J       Date:  2007-02-01       Impact factor: 11.598

4.  AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis.

Authors:  Per M Humpert; Ivan K Lukic; Suzanne R Thorpe; Stefan Hofer; Ezzat M Awad; Martin Andrassy; Elizabeth K Deemer; Michael Kasper; Erwin Schleicher; Markus Schwaninger; Markus A Weigand; Peter P Nawroth; Angelika Bierhaus
Journal:  J Leukoc Biol       Date:  2009-04-28       Impact factor: 4.962

5.  Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans.

Authors:  Michael Morcos; Xueliang Du; Friederike Pfisterer; Harald Hutter; Ahmed A R Sayed; Paul Thornalley; Naila Ahmed; John Baynes; Suzanne Thorpe; Georgi Kukudov; Andreas Schlotterer; Farastuk Bozorgmehr; Randa Abd El Baki; David Stern; Frank Moehrlen; Youssef Ibrahim; Dimitrios Oikonomou; Andreas Hamann; Christian Becker; Martin Zeier; Vedat Schwenger; Nexhat Miftari; Per Humpert; Hans-Peter Hammes; Markus Buechler; Angelika Bierhaus; Michael Brownlee; Peter P Nawroth
Journal:  Aging Cell       Date:  2008-01-21       Impact factor: 9.304

6.  Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.

Authors:  K C B Tan; W S Chow; A W K Tso; A Xu; H F Tse; R L C Hoo; D J Betteridge; K S L Lam
Journal:  Diabetologia       Date:  2007-07-18       Impact factor: 10.122

Review 7.  AGE, RAGE, and ROS in diabetic nephropathy.

Authors:  Adeline L Y Tan; Josephine M Forbes; Mark E Cooper
Journal:  Semin Nephrol       Date:  2007-03       Impact factor: 5.299

8.  Identification, classification, and expression of RAGE gene splice variants.

Authors:  Barry I Hudson; Angela M Carter; Evis Harja; Anastasia Z Kalea; Maria Arriero; Hojin Yang; Peter J Grant; Ann Marie Schmidt
Journal:  FASEB J       Date:  2007-12-18       Impact factor: 5.191

9.  The HMGB1 receptor RAGE mediates ischemic brain damage.

Authors:  Sajjad Muhammad; Waleed Barakat; Stoyan Stoyanov; Sasidhar Murikinati; Huan Yang; Kevin J Tracey; Martin Bendszus; Grazisa Rossetti; Peter P Nawroth; Angelika Bierhaus; Markus Schwaninger
Journal:  J Neurosci       Date:  2008-11-12       Impact factor: 6.167

10.  Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes.

Authors:  Per M Humpert; Zdenka Djuric; Stefan Kopf; Gottfried Rudofsky; Michael Morcos; Peter P Nawroth; Angelika Bierhaus
Journal:  Cardiovasc Diabetol       Date:  2007-03-07       Impact factor: 9.951

View more
  102 in total

1.  Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina.

Authors:  Q Wang; F Pfister; A Dorn-Beineke; F vom Hagen; J Lin; Y Feng; H P Hammes
Journal:  Diabetologia       Date:  2010-03-26       Impact factor: 10.122

2.  Influence of diabetes on endothelial cell response during sepsis.

Authors:  P Schuetz; K Yano; M Sorasaki; L Ngo; M St Hilaire; J M Lucas; W Aird; N I Shapiro
Journal:  Diabetologia       Date:  2011-02-01       Impact factor: 10.122

Review 3.  Inflammation: therapeutic targets for diabetic neuropathy.

Authors:  Jiyin Zhou; Shiwen Zhou
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

4.  Systemic activation of NF-κB driven luciferase activity in transgenic mice fed advanced glycation end products modified albumin.

Authors:  Norbert Nass; Kristina Bayreuther; Andreas Simm
Journal:  Glycoconj J       Date:  2017-02-13       Impact factor: 2.916

5.  A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease.

Authors:  Yangrong Zhang; Karen A Lapidos; Anca Gal-Moscovici; Stuart M Sprague; Guillermo A Ameer
Journal:  Artif Organs       Date:  2013-11-11       Impact factor: 3.094

6.  Oxidative stress and glucose metabolism--is there a need to revisit effects of insulin treatment?

Authors:  P M Humpert
Journal:  Diabetologia       Date:  2010-01-06       Impact factor: 10.122

7.  The possible role of esRAGE and sRAGE in the natural history of diabetic nephropathy in childhood.

Authors:  Cosimo Giannini; Ebe D'Adamo; Tommaso de Giorgis; Valentina Chiavaroli; Alberto Verrotti; Francesco Chiarelli; Angelika Mohn
Journal:  Pediatr Nephrol       Date:  2011-08-26       Impact factor: 3.714

8.  Soluble receptor for advanced glycation end products and risk of liver cancer.

Authors:  Kristin A Moy; Li Jiao; Neal D Freedman; Stephanie J Weinstein; Rashmi Sinha; Jarmo Virtamo; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

9.  Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.

Authors:  Y Yu; K F Hanssen; V Kalyanaraman; A Chirindel; A J Jenkins; A J Nankervis; P A Torjesen; H Scholz; T Henriksen; B Lorentzen; S K Garg; M K Menard; S M Hammad; J A Scardo; J R Stanley; M Wu; A Basu; C E Aston; T J Lyons
Journal:  BJOG       Date:  2012-08-20       Impact factor: 6.531

10.  The S100B/RAGE Axis in Alzheimer's Disease.

Authors:  Estelle Leclerc; Emmanuel Sturchler; Stefan W Vetter
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.